Table 2.

Patients’s baseline characteristics.

	n = 29
Gender
Male	24 (82.8%)
Female	5 (17.2%)
Age	64.1 ± 8.5
Male	64.4 ± 8.4
Female	62.6 ± 9.9
Ethnicity
Caucasian	26 (89.7%)
Asian	0 (0%)
Other	3 (10.3%)
Histology
Adenocarcinoma	19 (65.5%)
Squamous cell carcinoma	10 (34.5%)
PD-L1 expression
0%	9 (31.0%)
1–49%	9 (31.0%)
≥ 50%	11 (37.9%)
Performance status (ECOG)
0	6 (20.7%)
1	15 (51.7%)
2	8 (27.6%)
Smoking status
Active	9 (31.0%)
Former	18 (62.1%)
Never	2 (6.9%)
Treatment
Nivolumab	18 (62.1%)
Pembrolizumab	11 (37.9%)

Table 1 summarizes the baseline characteristics of the study cohort.

ECOG European Cooperative Oncology Group, PD-L1 Programed death ligand 1.